A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Breast Cancer · Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 235 (final count)
- Started
- Mar 14, 2022
- Main results expected
- Feb 26, 2027
- Fully finished
- Feb 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle
Measured over: Cycle 1 (28 days)
Number of participants with treatment emergent adverse events (AEs)
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Incidence of participants with clinical laboratory abnormalities
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Number of participants with vital signs abnormalities
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Number of participants with corrected QT (QTc) interval
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT05262400 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC